ARS Pharmaceuticals Inc (SPRY) saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.
During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market expectations. The company cited challenges with prior authorizations as a significant hurdle in driving initial prescriptions. Despite these obstacles, ARS Pharmaceuticals highlighted progress in securing payer coverage, with a goal of reaching 80% unrestricted commercial coverage by early summer 2025.
Looking ahead, ARS Pharmaceuticals outlined plans to accelerate adoption, including the launch of a direct-to-consumer advertising campaign in May 2025 and the introduction of a 1mg dose for children. The company also expects the upcoming availability of real-world data from its neffy Experience Program to boost physician confidence. However, investors appear to be taking a cautious stance, waiting to see if these initiatives will translate into significant sales growth in the coming quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.